AN2 TherapeuticsANTX -2.69%22 FCF Yield % is -18.48 as of Jul. 02, 2026. GuruFocus rates ANTX with a GF Score™ of 22/100. The stock has 4 warning signs investors should review. Among 1,414 Biotechnology companies, AN2 Therapeutics ranks worse than 64.43% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
AN2 Therapeutics FCF Yield % Related Terms
AN2 Therapeutics FCF Yield % Historical Data
* Premium members only.
The historical data trend for AN2 Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AN2 Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AN2 Therapeutics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AN2 Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where AN2 Therapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AN2 Therapeutics (ANTX) has a FCF Yield % of -18.48 as of Jul. 02, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on AN2 Therapeutics and its competitors. According to the industry distribution chart, AN2 Therapeutics ranks #911 out of 1414 companies in the Biotechnology industry, placing it in the top 64.4%.
Is AN2 Therapeutics' FCF Yield % too high?
AN2 Therapeutics' current FCF Yield % is -18.48. Based on the distribution chart, AN2 Therapeutics ranks #911 out of 1414 companies in the Biotechnology industry, which is below the industry midpoint. Overall, AN2 Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does AN2 Therapeutics' FCF Yield % compare to OKUR and KRRO?
According to the Biotechnology industry distribution chart, AN2 Therapeutics ranks #911 out of 1414 companies for FCF Yield %. This places AN2 Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on AN2 Therapeutics and its competitors. AN2 Therapeutics's current FCF Yield % is -18.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AN2 Therapeutics stock overvalued right now?
AN2 Therapeutics (ANTX) has a current FCF Yield % of -18.48. The current FCF Yield % is -18.48. AN2 Therapeutics' overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For AN2 Therapeutics (ANTX), the current FCF Yield % is -18.48 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
22GF Score
Get the complete analysis for ANTX
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANTX has been successfully added to your 
